This article explores how COVID-19 has impacted clinical investigation sites and what companies could do to mitigate the effect on trials moving forwards.
List view / Grid view
Contract Research Organisations (CROs)
Filter the results
G Balaji and Ravi Kalla explains how Pharma 4.0 can be implemented at a CRO to enable work to continue even during a global pandemic.
Researchers have revealed the top six CROs that dominate the Japanese market and are expected to continue in their position.
A new report has said that CROs are likely to resume their business activity in the second half of 2020 because of high demand.
European Pharmaceutical Review explores some of the latest developments in outsourcing, including clinical development and production agreements; acquisitions and collaborations; and expansions.
A group of four CROs at BioCity Nottingham have joined forces to collectively work on the research of COVID-19 therapies.
A PricewaterhouseCoopers report has highlighted the directions that the growth of the contract development and manufacturing organisation (CDMO) outsourcing market will take in the near future.
An outsourcing company has announced that Phase II, III and IV clinical trials of vaccines will continue at a growing number of sites, assessing the safety of each in light of COVID-19.
A report suggests the need for novel therapies and cost-effective R&D will drive growth for contract research organisations, especially in Asia-Pacific.
This article covers the analytical criteria that apply to Bacterial Endotoxin Testing (BET) using Limulus Amebocyte Lysate (LAL) or recombinant Horseshoe crab Factor C (rFC) for the bioactivity determination of endotoxin in aqueous solutions, such as pharmaceuticals and medical device extracts. It explains the importance of these criteria for accurate…
In the biopharmaceuticals industry today, only 13 percent of therapeutics that enter Phase 1 of clinical trials go on to launch1 – and the total journey from R&D to market can be anywhere between eight and 12 years.2
Companies often need to arrange for the synthesis of test substances to support research and development efforts.
FDA was perhaps understating a point when it said in its April 2016 Draft Guidance: Data Integrity and Compliance with cGMP that the increasing number of data integrity-related cGMP violations identified during its inspections was ‘troubling’...
4 April 2017 | By Christoph Huwe, Strategic Alliance Manager Therapeutics at Bayer Pharmaceuticals, Global External Innovation & Alliances
Ahead of the 7th Annual Strategic Alliance Management for Pharma conference, we spoke with Bayer's Christoph Huwe about the organisational development of alliance management...